What Has Been the Growth of the Inactivated Vaccines Market So Far?
The inactivated vaccines market has seen considerable growth due to a variety of factors.
• The market size for inactivated vaccines has been consistently increasing in the last few years. It is expected to rise from $6.19 billion in 2024 to $6.44 billion in 2025, with a compound annual growth rate (CAGR) of 4.0%.
The expansion during the historical timeframe was propelled by initiatives aimed at eradicating polio, influenza immunization schemes, the emergence of infectious diseases, and regulatory approvals.
What Is the Forecasted Market Size and Growth Rate for The Inactivated Vaccines Market Size In The Coming Years?
The inactivated vaccines market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for deactivated vaccines is predicted to experience consistent expansion in the upcoming years, reaching a value of $7.75 billion in 2029 with a compound annual growth rate (CAGR) of 4.7%.
This growth during the forecast period is due to preparedness for pandemics, increased vaccine coverage, advancements in biomanufacturing, and initiatives for health equity. Significant trends during this period are expected to include mRNA vaccine platforms, combined vaccines, thermostable vaccines, and digital vaccine passports.
What Factors Are Driving Growth In The Inactivated Vaccines Market?
The rise in infectious diseases is anticipated to catalyze the growth of the inactivated vaccine industry in the coming years. These diseases, caused by pathogens like bacteria, viruses, fungi, or parasites, can be easily transmitted from one person to another, leading to a variety of symptoms and health issues. Tuberculosis, for example, is a common infectious disease. Inactivated vaccines employ dead pathogens to trigger an immune response, which helps prevent diseases such as polio, hepatitis A, and influenza. As per an article from the US-based Centers for Disease Control and Prevention in November 2023, the count of tuberculosis patients in the USA had surged from 8,320 in 2022 to 9,615 in 2023, indicating an increase of 1,295 cases. Consequently, the escalating prevalence of infectious diseases is fueling the expansion of the inactivated vaccine market.
Growth of Inactivated Vaccines Market Through Increasing Immunization Initiatives
What Are The Main Segments Of The Global Inactivated Vaccines Market?
The inactivated vaccines market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine
2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
Subsegments:
1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine
2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine
Pre-Book The Inactivated Vaccines Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Inactivated Vaccines Industry?
Leading firms in the inactivated vaccines market are striving to maintain their market presence by launching advanced and innovative inactivated vaccines. These vaccines consist of inactivated virus particles, bacteria, or other pathogens, which are cultured and subsequently killed to eliminate the disease-causing ability. For example, the UK-headquartered pharmaceutical and biotechnology firm, GSK PLC, launched an innovative inactivated vaccine called Shingrix in January 2022, aimed at improving protection against shingles (Herpes zoster). Shingrix, an intramuscularly administered non-live, recombinant subunit adjuvanted vaccine, was initially indicated for individuals aged 50 years and above. More recently, the scope of Shingrix has been widened to include individuals aged 18 and above who are at an increased risk of getting shingles due to immunosuppression or immunodeficiency associated with specific illnesses or treatments.
Who Are the Key Players In The Inactivated Vaccines Market?
Major companies operating in the inactivated vaccines market are:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Sinopharm Group Co. Ltd.
• Merck & Co. Inc.
• Sanofi S.A.
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• CSL Limited
• Daiichi Sankyo Company Limited
• Mitsubishi Tanabe Pharma Corporation
• Novavax Inc.
• Zydus Lifesciences Ltd.
• Sinovac Biotech Ltd.
• Biological E Limited
• Hualan Biological Engineering Inc.
• CanSino Biologics Inc.
• Shenzhen Kangtai Biological Products Co. Ltd.
• Serum Institute of India Pvt. Ltd.
• Beijing Tiatan Biological Products Co. Ltd.
• Valneva SE
• Bavarian Nordic A/S.
• Beijing Minhai Biotechnology Co. Ltd.
• Bharat Biotech International Limited
• Panacea Biotec Ltd.
• Sinergium Biotech SA
• Bharat Immunologicals and Biologicals Corporation Limited
• Haffkine Biopharmaceutical Corporation LimitedIncepta Vaccine Ltd.
• Changchun BCHT Biotechnology Co. Ltd.
• .
What Is The Most Dominant Region In The Inactivated Vaccines Market?
North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
